SCHEMBL4637994

SCHEMBL4637994

COC(=O)c1ncn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.43
KDR P35968 2/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EGFR P00533 1/20 0.39
FGFR1 P11362 1/20 0.39
KCNH2 Q12809 1/20 0.39
IDH1 O75874 1/20 0.39
GRIN2B Q13224 3/20 0.38
GRIN1 Q05586 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP19A1 P11511 1/20 0.38
GPBAR1 Q8TDU6 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638859 0.89 SMN1; SMN2 (0.43) KDM4EHTTSMN1; SMN2KCNH2
SCHEMBL4638629 0.88 HCRTR1 (0.44) CFTRKDRHCRTR1HCRTR2KDM4E
SCHEMBL4638108 0.87 GPBAR1 (0.39) KDRHCRTR1HCRTR2GPBAR1
SCHEMBL4637999 0.82 IDH1 (0.46) CFTRKDRHCRTR1HCRTR2KDM4E
SCHEMBL4638631 0.80 CFTR (0.43) CFTRKDRHCRTR1HCRTR2KDM4E
SCHEMBL4638577 0.78 IDH1 (0.41) KDRSMN1; SMN2IDH1GRIN2BCYP11B1
SCHEMBL4639418 0.77 GRIN2B (0.40) KDRKDM4ESMN1; SMN2GRIN2BGRIN1
SCHEMBL4637805 0.77 GAA (0.52) KDM4EHTTSMN1; SMN2KCNH2
SCHEMBL4637930 0.77 TACR1 (0.43) KDM4EHTTSMN1; SMN2KCNH2
SCHEMBL4639437 0.75 TACR1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 CFTR 257/4885KDR 1389/4885HCRTR1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.